Results showed that patients with mutated KRAS colorectal cancer had 3 times the risk of developing thrombotic events as those with unmutated KRAS, making it the first study that showed the implication of a genetic mutation on the risk of developing thrombosis [15]. This evidence concerns the gene KRAS and colorectal cancer.